VRTX
VERTEX PHARMACEUTICALS INC / MA
NASDAQ · Healthcare · Biotechnology · US
$549.04
+3.44%Next report
Analyst consensus
- Next report date
- Feb 11, 2027
- EPS estimate
- $4.23
- Revenue estimate
- $3.5B
Latest reported
- Last report date
- Nov 2, 2026
- EPS actual
- $4.76
- EPS estimate
- $4.82
- Revenue actual
- $3.4B
- Revenue estimate
- $3.4B
Track record
Trailing twelve quarters
- EPS beats (12Q)
- 5
- EPS misses (12Q)
- 3
- EPS in line (12Q)
- 4
- Avg surprise (4Q)
- +0.6%
- Revenue beats (12Q)
- 8
Analyst ratings
Sell-side consensus
- Consensus
- Buy
- Price target
- $626
- PT range
- $563 – $725
- Analysts
- 11
10 Buy1 Hold0 Sell
Reported history
| Report date | EPS estimate | EPS actual | Surprise | Revenue actual |
|---|---|---|---|---|
| Nov 2, 2026 | $4.82 | $4.76 | Miss -1.24% | $3.4B |
| Aug 3, 2026 | $4.74 | $4.73 | Miss -0.21% | $3.3B |
| May 4, 2026 | $4.24 | $4.47 | Beat 5.42% | $3.0B |
| Feb 12, 2026 | $5.11 | $5.03 | Miss -1.57% | $3.2B |
| Aug 1, 2024 | -$12 | -$13 | Miss -10.32% | $2.6B |
| Aug 1, 2023 | $3.88 | $3.89 | Beat 0.28% | $2.5B |
| May 1, 2023 | $3.02 | $3.05 | Beat 0.96% | $2.4B |
| Feb 7, 2023 | $3.52 | $3.76 | Beat 6.82% | $2.3B |
| Oct 27, 2022 | $3.66 | $4.01 | Beat 9.68% | $2.3B |
| Aug 4, 2022 | $3.49 | $3.60 | Beat 3.18% | $2.2B |
| May 5, 2022 | $3.50 | $3.52 | Beat 0.72% | $2.1B |
| Jan 26, 2022 | $3.30 | $3.37 | Beat 2.18% | $2.1B |
Reported results against consensus at the time of each report · Surprise is computed from the estimate on record · Data as of Feb 11, 2027